Company intelligence / Profile preview

Axsome Therapeutics, Inc.

New York, New York, United Statesaxsome.com ↗

Ownership: Public · AXSM
Development stage: Other

Overview

Axsome has two commercial products (Auvelity for major depressive disorder and Sunosi for excessive daytime sleepiness) and a robust late-stage pipeline. Their lead candidate AXS-05 has shown positive results in three Phase 3 trials for Alzheimer's disease agitation with NDA submission planned for second half of 2025. AXS-12 showed positive Phase 3 results for narcolepsy in March 2024.

Therapeutic areas: PulmonologyPsychiatryNeurologyRheumatology
Modalities: Small moleculesNMDA receptor antagonistsDopamine and norepinephrine reuptake inhibitors
Industry: Biotech

Drug pipeline

9 assets

dextromethorphan

Approved

8 more assets in the full pipeline.

Partnerships

PharmanoviaSandoz Inc.Unichem Laboratories Ltd.

Financials

Market cap: $6.8B
Total revenue: $638.5M
Enterprise value: $6.7B

Beyond the preview

Go deeper on Axsome Therapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Axsome Therapeutics, Inc..